Please login to the form below

Not currently logged in
Email:
Password:

nintedanib

This page shows the latest nintedanib news and features for those working in and with pharma, biotech and healthcare.

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Those are the same conditions applied to Boehringer Ingelheim’s Ofev (nintedanib), the only other approved IPF treatment in the UK.

Latest news

More from news
Approximately 9 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    The drug is predicted to take a 50% share of the estimated $2bn IPF market, the main competitor being Boehringer Ingelheim's nintedanib currently in late stage development.

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    It's a method that is also seeing Boehringer enter the increasingly attractive rare diseases market through its investigational drug nintedanib, which is in studies assessing its effectiveness as a treatment ... This is in addition to nintedanib's

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics